论文部分内容阅读
目的:评估睾丸切除联合氟他胺与单纯睾丸切除或药物去势对于前列腺癌中晚期疗效研究。方法:采用分析前列腺癌中晚期病人36例进行评估。其中13例行睾丸切除联合氟他胺治疗,为A组;11例行单纯睾丸切除治疗,为B组;12例药物去势治疗,为C组。分析它们的主要疗效指标包括全周身情况、远处扩散性产生的疼痛、血清前列腺特异性抗原(PAS)水平、癌肿大小以及远处转移范围,5年生存率。对3组疗效进行差异评估。结果:A组较B组、C组有显著性差异,其中3组的5年生存率60%、62%、58%没有显著性差异。结论:前列腺癌内分泌治疗的金标准仍然是睾丸切除。睾丸切除联合氟他胺治疗在患者自身症状,后期周身疼痛的缓解、前列腺标志物(PSA)的变化和病变扩散方面较单纯睾丸切除有较好的效果。
OBJECTIVE: To evaluate the mid-to-late efficacy of orchidectomy combined with flutamide and orchidectomy or drug castration for prostate cancer. Methods: The analysis of 36 cases of advanced prostate cancer patients were evaluated. Among them, 13 patients underwent orchidectomy combined with flutamide, which was group A; 11 patients underwent simple orchiectomy, which was group B; and 12 patients underwent ovariectomy for group C. The primary efficacy indicators for their analysis included perioperative conditions, distant spread pain, serum prostate-specific antigen (PAS) levels, tumor size, distant metastasis, and 5-year survival. Differences in the efficacy of the three groups assessed. Results: There was significant difference between group A and group B and group C, and there was no significant difference between the three groups in 5 year survival rate of 60%, 62% and 58%. Conclusions: The gold standard for endocrine therapy of prostate cancer is still orchiectomy. Orchidectomy combined with flutamide treatment in patients with their own symptoms, postoperative pain relief, prostate markers (PSA) changes and lesions spread than simple orchiectomy has a good effect.